Overview

* Orchestra BioMed ( OBIO ) Q3 revenue beats analyst expectations at $0.9 mln

* Company secured $147.6 mln in proceeds from strategic transactions and equity offerings

* Expanded collaborations with Medtronic and Terumo, enhancing strategic partnerships

Outlook

* Company expects to complete Virtue Trial enrollment by mid-2027

* Orchestra BioMed extends cash runway into Q4 2027

* Company plans to complete BACKBEAT study enrollment by mid-2026

Result Drivers

* STRATEGIC TRANSACTIONS - Secured $147.6 mln in proceeds from strategic transactions and equity offerings to support clinical programs

* CLINICAL TRIAL PROGRESS - Initiated patient enrollments in the Virtue SAB U.S. pivotal trial, targeting mid-2027 for completion

* EXPANDED COLLABORATIONS - Strengthened partnerships with Medtronic and Terumo, including a new ROFR agreement with Terumo

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $900,000 $757,600

Revenue (5

Analysts

)

Q3 EPS -$0.40

Q3 Net -$20.80

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

* Wall Street's median 12-month price target for Orchestra Biomed Holdings Inc ( OBIO ) is $12.00, about 68.3% above its November 7 closing price of $3.81

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)